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The El Escorial criteria for the diagnosis of Amyotrophic Lateral
Sclerosis (ALS) were initially published in 1994 (Brooks, 1994) and
revised in 2000 (Brooks et al., 2000). Criteria were established
because the ‘‘variety of clinical features which may be present
early in the course of ALS makes absolute diagnosis difficult and
compromises the certainty of diagnosis for clinical research pur-
poses and therapeutic trials.” (Brooks, 1994) The original criteria
described 4 categories of disease: Definite, Probable, Possible,
and Suspected ALS. However, subsequent clinical experience made
it clear that non-Definite categories included patients who would
ultimately die of ALS with a high degree of clinical certainty. To
increase diagnostic sensitivity, the revised criteria (Brooks et al.,2000) included a category called ‘‘laboratory-supported probable
ALS” that allowed the use of Electromyography (EMG) data to sub-
stitute for clinical findings, and the category of ‘‘suspected ALS”
was deleted. While the remaining categories identified patients
with ALS with a high degree of specificity, many clinical neuro-
physiologists were concerned that sensitivity was compromised
because of the specific way EMG data contributed to the diagnosis
and noted that fibrillation-sharp wave potentials, defined as an
obligatory lower motor neuron sign, were often absent in other-
wise affected muscles (de Carvalho et al., 1999). To address these
perceived problems, the Awaji criteria (de Carvalho et al., 2008)
modified the revised El Escorial Criteria to further integrate elec-
trophysiological criteria with clinical examination findings, and
to add the presence of fasciculations as a lower motor neuron sign
that could substitute for fibrillation potentials-positive sharp
waves in muscles with neurogenic changes. The Awaji criteria
1976 J.M. Shefner et al. / Clinical Neurophysiology 131 (2020) 1975–1978eliminated the category of ‘laboratory-supported probable ALS’,
but maintained the definite, probable, and possible categories.
Many studies performed subsequent to the publication of the
Awaji criteria have demonstrated that use of these criteria mod-
estly improves the sensitivity of diagnosis of ALS as compared to
the revised El Escorial (Gawel et al., 2014; de Carvalho, 2012;
Boekestein et al., 2010). Some studies have suggested a loss of sen-
sitivity due to the Awaji Criteria eliminating the diagnostic cate-
gory of Laboratory Supported Probable ALS; however, this is
primarily due to the fact that some patients were moved from Lab-
oratory Probable ALS to Possible ALS (Higashihara et al., 2012). Pos-
sible ALS is in fact a definitive diagnosis, so that having an
increased number of patients so diagnosed does not truly represent
a loss of sensitivity. A recent multicenter study comparing criteria
has reaffirmed the increased sensitivity attained when the Awaji
Criteria are employed (Johnsen et al., 2019).
However, both the revised El Escorial and the Awaji criteria are
complex to apply and prone to error. A recent multicenter study of
inter-rater reliability of diagnoses made based on the Awaji and
revised El Escorial criteria presented clinical and electrophysiologi-
cal data from nearly 400 patients being evaluated for ALS to 8 neu-
rophysiologists of variable experience in ALS; test–retest
reliability was quite low for both criteria, with the diagnoses of
‘‘not-ALS” and ‘‘Definite ALS” showing better agreement than prob-
able or possible ALS, in particular when applying Awaji criteria
(Johnsen et al., 2019).
A second limitation to both the revised El Escorial criteria and
the Awaji revision relates to the multiple categories of ALS that
are defined. Definite, Probable, or Possible ALS are understandably
interpreted by patients and clinicians as assessments of the likeli-
hood that ALS is in fact the disease causing the symptoms the
patient is experiencing. However, all three categories describe
patients whose disease is in fact ALS, to a very high degree of diag-
nostic certainty. There is also no clear implication that patients
with possible ALS will evolve through the categories of probable
and definite disease. Disease progression may or may not proceed
in a manner that leads to the evolution of patients through all 3
categories. Indeed, a patient initially diagnosed as having possible
ALS may progress to death without ever satisfying criteria for prob-
able or definite disease. Traynor and colleagues (Traynor et al.,
2000) found that patients initially diagnosed with possible ALS
had a 22% chance of death from ALS even though their diagnostic
category did not change.
A third concern arising from current criteria is that patients
with upper motor neuron signs in 2 body regions are classified as
having possible ALS, even without the presence of any lower motor
neuron signs. Such patients may ultimately be diagnosed as having
Primary Lateral Sclerosis based on progressive upper motor neuron
dysfunction in the absence of lower motor neuron signs for at least
4 years after disease onset (Turner et al., 2020). These patients have
a more protracted disease course and may never show the lower
motor neuron decline that defines ALS.
Finally, in the years since the Awaji Criteria were published,
there have been significant advances in neurophysiological probes
of upper motor neuron dysfunction, as well as advances in imaging,
genetics, and the development of fluid biomarkers (Turner, 2018;
Rutkove et al., 2012; Turner et al., 2011). The presence of cognitive
and behavioural change, now known to occur in up to 50% of those
with ALS, and the association with Frontotemporal Dementia in
15% of patients, were not recognized in the original criteria
(Strong et al., 2017).
For all of these reasons, a consensus conference sponsored by
the International Federation of Clinical Neurophysiology, the
World Federation of Neurology, the ALS Association, and the
MND Association was convened September 27–29, 2019 at Gold
Coast, Australia to evaluate whether new guidelines could simplifydiagnosis and take into account new data that might be incorpo-
rated into the criteria for ALS. Attendees recognized that ALS can
involve more than the motor system, and that cognitive, beha-
vioural, and psychiatric disturbances can be part of the disease.
The current state of knowledge of the genetics of ALS was
reviewed, as were new modalities for assessing both peripheral
motor and central disease. While further research on methods to
assess both central and peripheral processes is required, recom-
mendations for modification of the existing criteria focused on
simplifying how the diagnosis can be established, and in establish-
ing a single clinical diagnostic entity rather than different disease
categories.
The following statements summarize our current understand-
ing of ALS.
1. ALS is a progressive disorder of the motor system
a. Clinically focal onset is most frequent, but a generalized
symptom onset is also recognized.
b. The motor disorder in ALS reflects both lower and upper
motor neuron dysfunction, but it is recognized that upper
motor neuron signs are not always clinically evident.
c. Evidence of lower motor neuron dysfunction can be derived
from clinical examination and/or from EMG.
d. For the purpose of diagnosis, evidence of upper motor neu-
ron dysfunction is currently derived from clinical
examination.
e. Supportive evidence of lower motor neuron dysfunction can
be derived from ultrasound detection of fasciculations from
multiple muscles (Tsugawa et al., 2018). Supportive evidence
of upper motor neuron dysfunction can be derived from
transcranial magnetic stimulation studies of the central
motor nervous system, MRI, and neurofilament levels
(Bowser et al., 2011). It should be stressed that current diag-
nosis does not require these studies.
2. ALS may include cognitive, behavioral and/or psychiatric abnor-
malities although these are not essential for diagnosis.
Our proposed diagnostic criteria are presented in Table 1. We
hope that the simplicity of the criteria below will allow them to
be used by both clinicians and in the clinical trial setting.
We note that these proposed criteria represent expert opinion
and validation studies should be performed to establish their util-
ity. It should be noted, however, that these criteria closely resem-
ble those previously required using the Awaji revision of the
revised El Escorial Criteria for the diagnosis of Possible ALS. Thus,
criteria very similar to what we propose have previously been
employed in clinical trials.
Several aspects of these simplified criteria merit discussion.
First it should be stressed that cognitive and behavioural changes
are common in ALS, and diagnostic criteria have already been
established (Strong et al., 2017) to categorize these changes. These
criteria should be included in current and future diagnostic classi-
fications of ALS. Second, despite the advances in the genetics of
ALS, the presence or absence of specific mutations currently plays
no role in the above criteria. This decision was made because the
presence of a risk factor does not in itself indicate the disease pro-
cess is taking place, while on the other hand the simple criteria
above are both necessary and sufficient. As gene therapies are
developed, it may become appropriate to modify the criteria to
allow specific gene variations to be taken into account. This will
require consensus on which gene variations should carry diagnos-
tic weight and will need to be reviewed periodically as new ALS
gene variations are discovered. Third, while the available data at
present do not support use of imaging or neurophysiological
modalities to establish the presence of upper motor neuron dys-
function, it is anticipated that future studies will allow such data
Table 1
Criteria for diagnosis of ALS.
1. Progressive motor impairment documented by history or repeated clinical assessment, preceded by normal motor function, and
2. Presence of upper1 and lower2 motor neuron dysfunction in at least 1 body region3 , (with upper and lower motor neuron dysfunction noted in the same body region
if only one body region is involved) or lower motor neuron dysfunction in at least 2 body regions, and
3. Investigations4 excluding other disease processes
Footnotes:
1Upper motor neuron dysfunction implies at least one of the following:
1. Increased deep tendon reflexes, including the presence of a reflex in a clinically weak and wasted muscle, or spread to adjacent muscles
2. Presence of pathological reflexes, including Hoffman sign, Babinski sign, crossed adductor reflex, or snout reflex.
3. Increase in velocity-dependent tone (spasticity)
4. Slowed, poorly coordinated voluntary movement, not attributable to weakness of lower motor neuron origin or Parkinsonian features
2Lower motor neuron dysfunction in a given muscle requires either:




EMG abnormalities that must include:
Both evidence of chronic neurogenic change, defined by large motor unit potentials of increased duration and/or increased amplitude, with polyphasia and motor
unit instability regarded as supportive but not obligatory evidence.
And evidence of ongoing denervation including
Fibrillation potentials or positive sharp waves, or
fasciculation potentials
3Body regions are defined as bulbar, cervical, thoracic and lumbosacral. To be classified as an involved region with respect to lower motor neuron involvement, there
must be abnormalities in two limb muscles innervated by different roots and nerves, or one bulbar muscle, or one thoracic muscle either by clinical examination or
by EMG.
4The appropriate investigations depend on the clinical presentation, and may include nerve conduction studies and needle EMG, MRI or other imaging, fluid studies of
blood or CSF, or other modalities as clinically necessary.
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tions is not required to make the diagnosis of ALS, we recognize
that diffuse fasciculations renders the diagnosis more likely, and
their absence should spur the clinician to consider other diagnoses
as appropriate. Fifth, it is recognized that both fluid and imaging
studies may ultimately allow for specific diagnosis, (for example,
a probe for the presence of TDP43 pathology). However, these
potential biomarkers remain at the experimental stage. Finally,
we feel that abnormalities should be grouped in body regions for
a diagnosis of ALS to be clear. Spotty abnormalities scattered
throughout the neuraxis may have a broader differential diagnosis
and be more prone to misdiagnosis than abnormalities occurring
consistently in one or more regions of the body. For that reason,
we have maintained the description of body regions in a manner
similar to the revised El Escorial Criteria. We have also maintained
the role of EMG/NCS in ALS diagnosis; in the opinion of the Consen-
sus Group, this test is a critically important although not obligatory
investigation aimed at eliminating other nerve diseases as possible
etiologies of LMN dysfunction, and facilitating diagnosis by identi-
fying muscles which clinically are not identified as showing evi-
dence of LMN dysfunction.
To summarize, the criteria as presented represent the minimum
necessary abnormalities to arrive at a diagnosis of ALS. The objec-
tive has been to simplify by collapsing the criteria for possible,
probable, and definite disease into a single entity from a clinicalmanagement perspective. Enrolment into clinical trials should
use these criteria for diagnostic purposes; we recognize that indi-
vidual clinical trials are likely to have additional inclusion criteria
which may further define the population to be studied within that
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